Glytec LLC Adds Pediatric Insulin Dosing to its IV and SubQ FDA Clearances
Published: May 22, 2012
Hypoglycemia, hyperglycemia, and, in particular, increased glucose variability are prevalent with pediatric intensive care patients and those children suffering with diabetes in general, all of which are issues associated with increased length of stay and mortality rates. Children pose unique treatment challenges related to medications, dietary control, meal planning and physical activity, all of which necessitate effective glycemic control.
Commenting on the announcement, Trefor Thomas, CEO & President of Glytec, said, "We're very pleased that the FDA has cleared our system for use with all children as young as two, and we expect to see substantial improvement in their outcomes, similar to what adult patients have been experiencing with our system for years."
Glytec's clinician-developed, algorithm-based insulin-dosing software is a network based application designed to consider each patient's insulin sensitivity to safely stabilize excursions while achieving and maintaining glucose levels within a clinician defined target range, allowing patients to achieve safe normoglycemia. This can translate to reductions in length of stay, infection rates, readmission rates, comorbidity, and even mortality.
Thomas added, "This latest advance again demonstrates Glytec to be the industry leader in glycemic management. Our organization has worked hard to earn the FDA clearance for an application designed around the unique needs of children, and we are excited to be the first to get clearance for pediatric dosing. We will continue to work on other ways to extend the safety and efficacy of insulin as a way to control elevated blood glucose levels without causing hypoglycemia."
About Glytec, LLC
Founded in 2006 and headquartered in Greenville, South Carolina, Glytec (http://www.GlytecSystems.com) is leading the way with next generation glycemic control management systems. Glytec offers the only glycemic management system cleared for both adults and children. For further information, contact: William J. Nicholson, Marketing Director, Glytec, LLC (864) 263 4178 email@example.com
Visit Glytec at NTI/AACN in Orlando, May 22 to 24 Booth #2437
SOURCE Glytec, LLC